無料プレビュー

MBX Biosciences, Inc. Common Stock (MBX) · NASDAQ Global Select

プロフィール

MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform. The company's lead programs include canvuparatide for chronic hypoparathyroidism (in Phase 3), MBX 4291 for obesity (in Phase 1), and imapextide for post-bariatric hypoglycemia (in Phase 2a). MBX markets to patient populations in the United States and Europe through planned internal commercial infrastructure and potential partnerships, focusing initially on geographically concentrated rare-disease indications.

主要指標

株価: $53.25 (-2.37%)
時価総額: 25億ドル
PER（今期予想）: -17.3
PBR: 6.2
配当利回り: —
52週レンジ: $12.94 – $72.64
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09